Malignant hyperthermia (MH) was first described as an inherited highly lethal disorder in 1960. There has since been significant progress in the clinical management, identification of MH susceptible (MHS) persons, and understanding of the underlying pathophysiology. When patients are known to be MHS prior to surgery, an MH episode can easily be avoided by the use of safe nontriggering anesthetic agents. Current MH mortality is _10%, but many experts believe this can be significantly reduced by improved MH preparedness. MH is triggered in humans by an MH triggering anesthetic agent, which causes the release of calcium from the sarcoplastic reticulum of the skeletal muscle cell at an uncontrolled rate resulting in a hypermetabolic state. Recent molecular genetic studies have shown that MH is related to an abnormal ryanodine receptor that controls the release of calcium from the sarcoplastic reticulum. This article reviews the current understanding of the pathophysiology, diagnosis, clinical presentation, and treatment of MH.
Thermoregulation| April 01 2004
Malignant Hyperthermia: Pathophysiology, Clinical Presentation, and Treatment
E. Jane McCarthy, CRNA, PhD, FAAN
AACN Adv Crit Care (2004) 15 (2): 231–237.
- Views Icon Views
- Share Icon Share
- Tools Icon Tools
- Search Site
E. Jane McCarthy; Malignant Hyperthermia: Pathophysiology, Clinical Presentation, and Treatment. AACN Adv Crit Care 1 April 2004; 15 (2): 231–237. doi: https://doi.org/
Download citation file: